BACKGROUND: Guidelines suggest that patients with nondysplastic Barrett's esophagus (BE) undergo endoscopic surveillance every 3 to 5 years, but actual use of surveillance endoscopy and the determinants of variation in surveillance intervals are not known. OBJECTIVE: To measure use of surveillance endoscopy and its variation in patients with nondysplastic BE. DESIGN: Multicenter, cross-sectional study. SETTING: Three sites in Arizona, Minnesota, and North Carolina. PATIENTS: This study involved patients who had prevalent BE without a history of high-grade dysplasia or esophageal adenocarcinoma. INTERVENTION: Participants were given validated measures of quality of life, numeracy, and cancer risk perception, and the total number of prior endoscopic surveillance examinations was measured. MAIN OUTCOME MEASUREMENTS: Oversurveillance was defined as >1 surveillance examination per 3-year period. RESULTS: Among 235 patients with nondysplastic BE, 76% were male and 94% were white. The average (± standard deviation [SD]) duration of BE was 6.5 ± 5.9 years. The mean (± SD) number of endoscopies per 3-year period was 2.7 ± 2.6. Oversurveillance was present in 65% of participants, resulting in a mean of 2.3 excess endoscopies per patient. Neither numeracy skills nor patient perception of cancer risk were associated with oversurveillance. LIMITATIONS: Endoscopies were measured by patient report, which is subject to error. Results may be generalizable only to patients seen in academic centers. CONCLUSION: Most patients with nondysplastic BE had more surveillance endoscopic examinations than is recommended by published guidelines. Patient factors did not predict oversurveillance, indicating that other factors may influence decisions about the interval and frequency of surveillance examinations.
BACKGROUND: Guidelines suggest that patients with nondysplastic Barrett's esophagus (BE) undergo endoscopic surveillance every 3 to 5 years, but actual use of surveillance endoscopy and the determinants of variation in surveillance intervals are not known. OBJECTIVE: To measure use of surveillance endoscopy and its variation in patients with nondysplastic BE. DESIGN: Multicenter, cross-sectional study. SETTING: Three sites in Arizona, Minnesota, and North Carolina. PATIENTS: This study involved patients who had prevalent BE without a history of high-grade dysplasia or esophageal adenocarcinoma. INTERVENTION: Participants were given validated measures of quality of life, numeracy, and cancer risk perception, and the total number of prior endoscopic surveillance examinations was measured. MAIN OUTCOME MEASUREMENTS: Oversurveillance was defined as >1 surveillance examination per 3-year period. RESULTS: Among 235 patients with nondysplastic BE, 76% were male and 94% were white. The average (± standard deviation [SD]) duration of BE was 6.5 ± 5.9 years. The mean (± SD) number of endoscopies per 3-year period was 2.7 ± 2.6. Oversurveillance was present in 65% of participants, resulting in a mean of 2.3 excess endoscopies per patient. Neither numeracy skills nor patient perception of cancer risk were associated with oversurveillance. LIMITATIONS: Endoscopies were measured by patient report, which is subject to error. Results may be generalizable only to patients seen in academic centers. CONCLUSION: Most patients with nondysplastic BE had more surveillance endoscopic examinations than is recommended by published guidelines. Patient factors did not predict oversurveillance, indicating that other factors may influence decisions about the interval and frequency of surveillance examinations.
Authors: William K Hirota; Marc J Zuckerman; Douglas G Adler; Raquel E Davila; James Egan; Jonathan A Leighton; Waqar A Qureshi; Elizabeth Rajan; Robert Fanelli; Jo Wheeler-Harbaugh; Todd H Baron; Douglas O Faigel Journal: Gastrointest Endosc Date: 2006-04 Impact factor: 9.427
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: Alexander C Ford; David Forman; P Dominic Reynolds; Brian T Cooper; Paul Moayyedi Journal: Am J Epidemiol Date: 2005-08-02 Impact factor: 4.897
Authors: Michael D Kappelman; Athos Bousvaros; Jeffrey Hyams; James Markowitz; Marian Pfefferkorn; Subra Kugathasan; Joel Rosh; Anthony Otley; David Mack; Anne Griffiths; Jonathan Evans; Richard Grand; Christine Langton; Ken Kleinman; Jonathan A Finkelstein Journal: Inflamm Bowel Dis Date: 2007-07 Impact factor: 5.325
Authors: Robert E Schoen; Paul F Pinsky; Joel L Weissfeld; Lance A Yokochi; Douglas J Reding; Richard B Hayes; Timothy Church; Susan Yurgalevich; V Paul Doria-Rose; Tom Hickey; Thomas Riley; Christine D Berg Journal: Gastroenterology Date: 2009-10-08 Impact factor: 22.682
Authors: Jennifer Arney; Marilyn Hinojosa-Lindsey; Richard L Street; Jason Hou; Hashem B El-Serag; Aanand D Naik Journal: Dig Dis Sci Date: 2014-02-06 Impact factor: 3.199
Authors: Anna Tavakkoli; Henry D Appelman; David G Beer; Chaitra Madiyal; Maryam Khodadost; Kimberly Nofz; Val Metko; Grace Elta; Thomas Wang; Joel H Rubenstein Journal: Clin Gastroenterol Hepatol Date: 2018-02-09 Impact factor: 11.382
Authors: M Hinojosa-Lindsey; J Arney; S Heberlig; J R Kramer; R L Street; H B El-Serag; A D Naik Journal: Dis Esophagus Date: 2013-02-05 Impact factor: 3.429
Authors: Hashem B El-Serag; Zhigang Duan; Marilyn Hinojosa-Lindsey; Jason Hou; Mohammad Shakhatreh; Aanand D Naik; G John Chen; Richard L Street; Jennifer R Kramer Journal: Gastrointest Endosc Date: 2012-10 Impact factor: 9.427
Authors: Aanand D Naik; Marilyn Hinojosa-Lindsey; Jennifer Arney; Hashem B El-Serag; Jason Hou Journal: Clin Gastroenterol Hepatol Date: 2013-05-09 Impact factor: 11.382